Who Generates Higher Gross Profit? Eli Lilly and Company or Dr. Reddy's Laboratories Limited

Eli Lilly vs. Dr. Reddy's: A Decade of Gross Profit Trends

__timestampDr. Reddy's Laboratories LimitedEli Lilly and Company
Wednesday, January 1, 20147580100000014683100000
Thursday, January 1, 20158540300000014921500000
Friday, January 1, 20169228100000015567200000
Sunday, January 1, 20177835600000016801100000
Monday, January 1, 20187630400000016811600000
Tuesday, January 1, 20198343000000017598300000
Wednesday, January 1, 20209400900000019056500000
Friday, January 1, 202110307700000021005600000
Saturday, January 1, 202211384000000021911600000
Sunday, January 1, 202320297200000027041900000
Monday, January 1, 202416360700000036624400001
Loading chart...

Cracking the code

A Tale of Two Giants: Eli Lilly vs. Dr. Reddy's Laboratories

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market dominance. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outperformed Eli Lilly and Company in terms of gross profit. From 2014 to 2023, Dr. Reddy's gross profit surged by approximately 167%, peaking in 2023. In contrast, Eli Lilly's growth was more modest, with a 84% increase over the same period.

While Eli Lilly's gross profit reached its highest in 2023, it still lagged behind Dr. Reddy's by a significant margin. This disparity highlights the strategic differences and market positioning of these two pharmaceutical powerhouses. As we look to the future, the absence of data for 2024 for Eli Lilly leaves room for speculation on whether it can close the gap.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025